Mirum Pharma Acquires Its Licensing Partner In Cash and Stock
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) has acquired Satiogen Pharmaceuticals Inc in a cash and stock deal. The deal consideration includes 841,792 shares, 199,993 of which are subject to the achievement of a milestone, and approximately $2.8 million in cash. Mirum will wholly own the Satiogen subsidiary, which will receive a 2% royalty. Satiogen was an…
Benzinga ·
Benzinga
